Summit Therapeutics and China-based Akeso have reported new Western data for ivonescimab, their PD-1/VEGF-targeting lung cancer antibody. The findings suggest that the drug’s efficacy may extend beyond Chinese patients. However, the case highlights a wider regulatory problem: strong Phase 3
